Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Bullboard (NDAQ:GRCE)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Post by MikeTesteron Aug 02, 2024 1:45pm

Acasti Pharma (NASDAQ:ACST): A Promising Specialty Pharmaceu

https://beyondspx.com/2024/07/31/acasti-pharma-nasdaqacst-a-promising-specialty-pharmaceutical-company-focused-on-rare-and-orphan-diseases-2/
31
Post by bingostaron Dec 22, 2022 6:08pm

the perfect situation

With a market cap  trading  under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you cannot dream of a better scenario . On top of it the CEO Pierre ...more  
477
Discussion
Comment by Canadian_101on Nov 21, 2022 3:26pm

RE:GTX-104 positive results

No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when they delayed their results for capri, I would not invest a dime in ...more  
211
Discussion
Post by bingostaron May 18, 2022 1:19pm

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints :: Acasti Pharma Inc. (ACST) They have 3 products ...more  
370
Discussion
Post by Betteryear2on Apr 25, 2022 8:45am

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial ...more  
250
Post by alanmar1on Apr 03, 2022 4:21pm

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never been fully ex[plained.Later the promise of licensing Care pre ...more  
379
Comment by flush777on Jan 05, 2022 1:56pm

RE:Over 200K on the bid, which is 1% of outstanding shares

Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low hanging fruit awaiting conference news... hopefully very very ...more  
281
Discussion
Comment by flush777on Jan 05, 2022 1:51pm

RE:Oppenheimer report on Acasti, outperform, target US $6

ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report ... except that it takes time for analysis and thoughts and yes, I ...more  
384
Discussion
Post by flush777on Jan 05, 2022 12:45pm

Oppenheimer report on Acasti, outperform, target US $6

Report dated Dec 21, 2021 ... Hum, graph looks great for any potential investor ...
384
Discussion
Post by flush777on Jan 05, 2022 12:26pm

Over 200K on the bid, which is 1% of outstanding shares

being whittled away at $1.85. Really good sign for the future!
301
Discussion
Post by Francine01on Dec 06, 2021 11:12am

SP Value

SP value is below cash in bank account. I didn't knew that this could be possible for a plublic company. Good job Jan! 
216
Comment by Canadian_101on Nov 06, 2021 10:12am

RE:For the record

What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me  something was majorly wrong when they delayed the ...more  
265
Discussion
Comment by 19LDS84on Oct 06, 2021 8:45pm

RE:Awarded Composition-of-Matter Patents for GTX-101

The best news here is the parents are good until 2036, which gives Jan plenty of time to f#$k this up again.... glta
198
Discussion
Post by Betteryear2on Oct 06, 2021 8:34am

Awarded Composition-of-Matter Patents for GTX-101

LAVAL, Qubec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office ...more  
303
Discussion
Post by alanmar1on Oct 02, 2021 11:01am

Acasti pharma

This is directed to Francine ,a dedicated ACST follower and righty so based on data available. Francine, if you still own ACST stock I recomend you move some of your investment  into WML. You ...more  
333
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities